Formulations of ladostigil tartrate
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, Technion Research & Development Foundation Limited
InventorsDaniella Licht, Ioana Lovinger, Fanny Caciularu, Adrian Gilbert
Life of this patent
Estimating the term…
Abstract
Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.
Claims26
A pharmaceutical composition comprising R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water.
A pharmaceutical composition comprising R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 0.5% by weight of the composition of magnesium stearate.
A pharmaceutical composition comprising R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and no more than 1.5% by weight of the composition of sodium stearyl fumarate.
9-14. (canceled)
16-22. (canceled)
A pharmaceutical composition comprising R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier, formulated so as to provide upon administration to a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL.
31-37. (canceled)
A method for inducing in a human subject a maximum blood plasma concentration of R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan of at least 0.7 nmol/mL after one administration, comprising administering orally to the human subject a solid pharmaceutical composition comprising R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate and a pharmaceutically acceptable carrier so as to induce in the subject the blood plasma concentration.
39-41. (canceled)
43-46. (canceled)
48-50. (canceled)
Dependencies are inferred from the claim text.